A Single-Center Clinical Study on the Efficacy and Safety of Xinwell Ureteroscope
Launched by SECOND AFFILIATED HOSPITAL, SCHOOL OF MEDICINE, ZHEJIANG UNIVERSITY · Jul 14, 2025
Trial Information
Current as of July 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is testing a new medical device called the Xinwell Ureteroscope, designed to help adults with kidney or ureter stones that are 1 to 3 centimeters in size. The study aims to find out if this tool is safe and effective in breaking up and removing stones during surgery. The Xinwell Scope has special features like flushing, suction, and pressure control to help clear stones more easily while protecting the kidney during the procedure.
People who join the study will have surgery using the Xinwell Scope to remove their stones. A CT scan will be done within 24 hours after surgery to see how well the stones were cleared. Then, about four weeks later, participants will have another imaging test and a health check to make sure there are no problems from the surgery. To be eligible, participants must be adults between 18 and 80 years old with stones in the upper urinary tract that meet the size requirements, and they need to be able to understand the study and agree to take part. Certain conditions, like recent infections, pregnancy, past kidney surgery, or severe health problems, may exclude someone from joining. This study is currently recruiting patients who meet these criteria.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients with upper urinary tract calculi, where the maximum diameter of a single calculus or the cumulative diameter of multiple calculi is 1-3 cm
- • 2. Patients who choose to undergo "flexible ureteroscopic holmium laser lithotripsy"
- • 3. Aged 18-80 years, regardless of gender
- • 4. Subjects without mental illness or language dysfunction, who can understand the details of this study and sign the informed consent form
- Exclusion Criteria:
- • 1. Patients with ureteral stricture or a history of ureteral stricture
- • 2. Patients with a history of open renal and/or ureteral surgery or laparoscopic surgery
- • 3. Fever (body temperature ≥ 38℃) due to urinary tract infection or other reasons within one week before surgery
- • 4. Pregnant women, lactating women, or women who are in the menstrual period
- • 5. ASA classification \> Grade 3: patients with severe systemic diseases, heart diseases, pulmonary insufficiency, and failure of important organ functions, etc., who cannot tolerate anesthesia or surgery
- • 6. Patients with anatomical malformations such as polycystic kidney, horseshoe kidney, and ectopic kidney
- • 7. Patients with abnormal coagulation function (e.g., international normalized ratio (INR) \> 1.5 or platelet count \< 80 × 10⁹/L)
- • 8. Patients with failed sheath placement during surgery
About Second Affiliated Hospital, School Of Medicine, Zhejiang University
The Second Affiliated Hospital of Zhejiang University School of Medicine is a leading clinical research institution dedicated to advancing healthcare through innovative medical practices and rigorous scientific inquiry. With a robust infrastructure and a multidisciplinary team of experienced researchers and clinicians, the hospital is committed to conducting high-quality clinical trials that address critical health challenges. As an integral part of Zhejiang University, the hospital leverages academic expertise and cutting-edge technology to foster collaboration in research, education, and patient care, ultimately aiming to improve patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Trial Officials
Bohan Wang, MD., Ph.D
Principal Investigator
2nd Affiliated Hospital, School of Medicine, Zhejiang University, China
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported